Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 8.38% is 20% above its 5-year average of 7.00%, near the high end of its 5-year range (1.76%–10.93%).
17.19% below its 12-month average of 10.12%.
Annual fiscal-year return on equity; no daily interpolation.
RETURN ON EQUITY (ROE)
8.38%
RETURN ON EQUITY (ROE) AVG TTM
10.12%
RETURN ON EQUITY (ROE) AVG 3Y
7.00%
RETURN ON EQUITY (ROE) AVG 5Y
7.00%
RETURN ON EQUITY (ROE) AVG 10Y
7.29%
RETURN ON EQUITY (ROE) AVG 15Y
9.08%
RETURN ON EQUITY (ROE) AVG 20Y
9.95%
CURRENT VS TTM AVG
-17.19%
CURRENT VS 3Y AVG
+19.71%
CURRENT VS 5Y AVG
+19.80%
CURRENT VS 10Y AVG
+14.98%
CURRENT VS 15Y AVG
-7.68%
CURRENT VS 20Y AVG
-15.74%
SECTOR MEDIAN · HEALTHCARE
13.38%
median of 76 covered companies
CURRENT VS SECTOR MEDIAN
-37.37%
vs the sector median at left
Market Cap
$23.41B
Return on Equity (ROE)
-6.79%
TTM Avg
-4.55%
3Y Avg
10.63%
5Y Avg
21.70%
Market Cap
$23.66B
Return on Equity (ROE)
-46.61%
TTM Avg
-32.64%
3Y Avg
-13.90%
5Y Avg
0.25%
Market Cap
$22.26B
Return on Equity (ROE)
20.48%
TTM Avg
18.68%
3Y Avg
17.25%
5Y Avg
16.03%
Market Cap
$24.84B
Return on Equity (ROE)
25.41%
TTM Avg
12.92%
3Y Avg
11.29%
5Y Avg
9.83%
Market Cap
$25.06B
Return on Equity (ROE)
18.89%
TTM Avg
16.95%
3Y Avg
19.08%
5Y Avg
20.56%
Market Cap
$26.25B
Return on Equity (ROE)
14.13%
TTM Avg
13.34%
3Y Avg
14.07%
5Y Avg
18.07%
Market Cap
$26.27B
Return on Equity (ROE)
11.65%
TTM Avg
9.71%
3Y Avg
9.35%
5Y Avg
12.84%
Market Cap
$19.04B
Return on Equity (ROE)
-2.88%
TTM Avg
-13.64%
3Y Avg
-4.29%
5Y Avg
-4.38%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| STERIS plc (STE) | $23.06B | 8.38% | 10.12% | 7.00% | 7.00% |
| BioNTech SE (BNTX)vs › | $23.41B | -6.79% | -4.55% | 10.63% | 21.70% |
| Moderna, Inc. (MRNA)vs › | $23.66B | -46.61% | -32.64% | -13.90% | 0.25% |
| United Therapeutics Corporation (UTHR)vs › | $22.26B | 20.48% | 18.68% | 17.25% | 16.03% |
| Incyte Corporation (INCY)vs › | $24.84B | 25.41% | 12.92% | 11.29% | 9.83% |
| West Pharmaceutical Services, Inc. (WST)vs › | $25.06B | 18.89% | 16.95% | 19.08% | 20.56% |
| Quest Diagnostics Incorporated (DGX)vs › | $26.25B | 14.13% | 13.34% | 14.07% | 18.07% |
| Labcorp Holdings Inc. (LH)vs › | $26.27B | 11.65% | 9.71% | 9.35% | 12.84% |
| Viatris Inc. (VTRS)vs › | $19.04B | -2.88% | -13.64% | -4.29% | -4.38% |
| Zimmer Biomet Holdings, Inc. (ZBH)vs › | $18.69B | 6.39% | 6.40% | 5.73% | 4.16% |
ROE
8.4%
ROA
5.6%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-03-31 | 10.93% |
| 2025-03-31 | 9.31% |
| 2024-03-31 | 6.00% |
| 2023-03-31 | 1.76% |
| 2022-03-31 | 3.73% |
| 2021-03-31 | 10.24% |
| 2020-03-31 | 11.97% |
| 2019-03-31 | 9.57% |
| 2018-03-31 | 9.07% |
| 2017-03-31 | 3.93% |
| 2016-03-31 | 3.66% |
| 2015-03-31 | 12.60% |
| 2014-03-31 | 12.46% |
| 2013-03-31 | 16.93% |
| 2012-03-31 | 16.57% |
| 2011-03-31 | 6.51% |
| 2010-03-31 | 17.04% |
| 2009-03-31 | 15.42% |
| 2008-03-31 | 10.92% |
| 2007-03-31 | 10.61% |
| 2006-03-31 | 9.62% |
| 2005-03-31 | 11.38% |
| 2004-03-31 | 13.85% |
| 2003-03-31 | 13.95% |
| 2002-03-31 | 9.48% |
| 2001-03-31 | 0.31% |
| 2000-03-31 | 2.49% |
| 1999-03-31 | 19.48% |
| 1998-03-31 | 18.25% |
| 1997-03-31 | -10.38% |
